Related Experiment Video
Updated: Apr 13, 2026

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
[New perspectives in the approach to age-related macular degeneration]
R Gallego-Pinazo1, M A Zapata2
1Unidad de Mácula, Servicio de Oftalmología, Hospital Universitario y Politécnico La Fe, Valencia, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España.
Abstract:
The approval of aflibercept for the neovascular form of age-related macular degeneration has opened up the possibility of treating patients with fewer injections, since the drug can be administered once every two months. Aflibercept can also be used as rescue therapy in patients with suboptimal response to other antiangiogenic treatments. The present study reviews the scientific evidence on aflibercept, both in treatment-naïve patients and in those with an unsatisfactory response to conventional treatments.
More Related Videos
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
iPS Cell Differentiation
Angle Closure Glaucoma: Treatment
Glaucoma: Overview

